Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NRD 135S E1

Drug Profile

NRD 135S E1

Alternative Names: E1; NRD E1; NRD.E1; NRD135S; NRD135S-E1; NRD135S.E1; NRD135SE.1

Latest Information Update: 30 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novaremed
  • Class Alcohols; Amides; Anti-inflammatories; Benzene derivatives; Non-opioid analgesics; Phenols; Small molecules
  • Mechanism of Action Lyn protein-tyrosine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain

Most Recent Events

  • 16 Sep 2022 Phase-II clinical trials in Neuropathic pain in USA (PO) (NCT05480228)
  • 21 Jul 2022 NRD 135S E1 licensed to NeuroFront for peripheral neuropathy and neuropathic pain in China, Hong Kong, Macau, Taiwan and Singapore
  • 23 Jun 2022 Efficacy and safety data from a phase II trial in Neuropathic pain released by Novaremed
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top